Expert Opinion on Drug Delivery is a leading journal in the field of pharmaceutical science, published by Taylor & Francis Ltd. With an impressive impact factor and a prestigious Q1 ranking in 2023, it stands out as a vital resource for researchers, professionals, and students dedicated to advancing drug delivery technologies. Established in 2004, the journal has consistently provided a platform for critical insights and expert analyses, bridging the gap between innovation and application in drug delivery systems. Although it currently does not offer Open Access options, the journal's rigorous peer-review process ensures the dissemination of high-quality research that significantly contributes to the fields of pharmacology, toxicology, and pharmaceutics. With its robust ranking of 13th out of 183 in Scopus, the journal continues to foster discourse and collaboration among experts, thereby enhancing the advancement of therapeutic options and improving patient outcomes.

Drug Development and Industrial Pharmacy is a prestigious journal published by Taylor & Francis Ltd, focusing on the critical field of pharmaceutical sciences. With an ISSN of 0363-9045 and an E-ISSN of 1520-5762, the journal has been an essential resource for researchers and professionals since its inception in 1974. It occupies a crucial niche within Drug Discovery, Organic Chemistry, and Pharmaceutical Science, currently ranked in the second and third quartiles, reflecting its solid contribution to the field. The journal encompasses a wide array of topics, including drug development processes, formulation, and industrial manufacturing alongside cutting-edge research in pharmacology and toxicology. With a commendable Scopus ranking demonstrating high relevance—ranked #44 in Pharmaceutical Science—it serves as a vital forum for academia and industry to share innovative findings and methodologies. While it does not offer open access, the journal remains an invaluable resource for those seeking to advance their knowledge and enhance their research in pharmaceutical development.

International Journal of Pharmaceutical Investigation, published by INPHARM ASSOC, PHCOG NET, is a premier platform dedicated to advancing the field of pharmaceutical sciences. With the ISSN 2230-973X and E-ISSN 2230-9713, this journal serves as a vital resource for researchers, professionals, and students focused on drug development, formulation, and efficacy. By fostering a rich discourse on innovative pharmaceutical practices and research breakthroughs, the journal plays a critical role in enhancing global health outcomes through groundbreaking scholarly work. The absence of open access allows for selective dissemination of high-quality content, promoting rigorous peer-review processes that uphold academic integrity. Featuring articles that span a diverse range of topics within pharmaceutical sciences, the International Journal of Pharmaceutical Investigation is committed to supporting the ongoing evolution of this dynamic field, making it an essential read for anyone engaged in pharmaceutical research and development.

Drug Delivery and Translational Research (ISSN: 2190-393X | E-ISSN: 2190-3948), published by Springer Heidelberg, stands at the forefront of the Pharmaceutical Sciences discipline, boasting a prestigious impact factor as evidenced by its Q1 category ranking in 2023. This esteemed journal is dedicated to the vital intersection of drug delivery systems and translational research, aiming to bridge the gap between laboratory findings and clinical applications. It features groundbreaking studies that enhance our understanding of drug pharmacokinetics, formulations, and patient-centered research, making it indispensable for researchers, professionals, and students striving to innovate and excel in the field. While the journal operates under a subscription model, its commitment to disseminating high-quality research is reflected in its Scopus rank, placing it in the top 6% of its category (Rank #11/183, 94th percentile). Since its inception in 2011, it has garnered significant attention, promoting advances in pharmacology, toxicology, and pharmaceutics, and continues to be a platform for vital discourse and discovery.

European Journal of Pharmaceutics and Biopharmaceutics is a leading academic journal published by Elsevier, dedicated to advancing the field of pharmaceutical sciences through high-quality research. Established in 1991, this multidisciplinary journal offers a platform for the dissemination of innovative findings in pharmaceutics and biopharmaceutics, covering crucial aspects such as drug formulation, delivery systems, and the interface of pharmaceutical formulation with biological systems. The journal is well-regarded for its impact, earning a Q1 status in Pharmaceutical Science and consistent Q2 rankings in both Biotechnology and Medicine (Miscellaneous) categories in 2023, thereby highlighting its significance in the scientific community. With an impressive Scopus ranking of 26th percentile in Pharmaceutical Science and 60th percentile in Biotechnology, it positions itself firmly at the forefront of research, supporting researchers, professionals, and students in their quest to address complex health challenges. While the journal does not offer an open-access option, it facilitates a rigorous peer-review process, ensuring that published articles meet the highest standards of scientific integrity. For those looking to make meaningful contributions to the field, the European Journal of Pharmaceutics and Biopharmaceutics serves as an essential resource and reference point.

Therapeutic Delivery is a prestigious journal dedicated to advancing the field of Pharmaceutical Science, published by Newlands Press Ltd. Since its inception in 2010, this journal has become a vital resource for researchers and professionals alike, focusing on innovative drug delivery systems and therapeutic approaches that enhance patient care. With an impressive impact factor reflective of its credibility and scholarly influence, Therapeutic Delivery is currently ranked in the Q2 quartile and placed at Rank #64 out of 183 in the realm of Pharmacology, Toxicology, and Pharmaceutics, showcasing its prominence in the field. The journal operates with an Open Access format, ensuring that groundbreaking research is readily available to a global audience. Based in the United Kingdom, it publishes comprehensive articles that cover a wide spectrum of topics within pharmaceutical sciences, from molecular mechanisms to clinical applications, thus catering to both academic and professional readerships. Researchers, students, and industry professionals will find Therapeutic Delivery an invaluable platform for sharing insights and fostering advancements in therapeutic methodologies.

The Journal of Pharmaceutical Innovation, published by SPRINGER, serves as a vital resource in the fields of Pharmaceutical Science and Drug Discovery. With an ISSN of 1872-5120 and an E-ISSN of 1939-8042, this journal has been disseminating significant research findings since its inception in 2006. It is recognized for its rigorous peer-review process, maintaining a respectable ranking of Q2 in Pharmaceutical Science and Q3 in Drug Discovery as of 2023. Researchers and practitioners benefit from the journal's diverse scope, which encompasses innovative methodologies and advancements in pharmaceuticals, thereby fostering knowledge and collaboration within the scientific community. Although it does not offer Open Access options, the journal is accessible through institutional subscriptions and libraries, ensuring that critical insights in drug development and pharmacology reach a broad audience. The geographical presence of the journal in the United States underscores its influence in shaping the pharmaceutical landscape on a global scale.

The Journal of Aerosol Medicine and Pulmonary Drug Delivery, published by MARY ANN LIEBERT, INC, is a distinguished journal dedicated to advancing the field of aerosol medicine and pharmacology. With an ISSN of 1941-2711 and E-ISSN 1941-2703, the journal has established itself as an essential resource for researchers and professionals specializing in pharmaceutical sciences and pulmonary medicine. Ranking in the Q2 category across multiple disciplines, including Pharmaceutical Science and Pulmonary and Respiratory Medicine, it holds notable Scopus rankings, with a percentile of 78th in Pulmonary and Respiratory Medicine. The journal offers open access options, ensuring that cutting-edge research is readily available to a global audience. With converged years from 2008 to 2024, the Journal of Aerosol Medicine and Pulmonary Drug Delivery continues to serve as a vital platform for disseminating innovative research findings, clinical practice insights, and technological advancements in drug delivery systems, thereby significantly impacting therapeutic strategies for respiratory diseases.

PHARMACEUTICAL RESEARCH, published by SPRINGER/PLENUM PUBLISHERS, is a leading journal in the ever-evolving field of pharmaceutical sciences. With an ISSN of 0724-8741 and an E-ISSN of 1573-904X, this journal has established itself as a critical hub for disseminating innovative research from 1984 to 2024. The journal holds impressive rankings in prominent categories, including Q2 in Biotechnology and Q2 in Pharmaceutical Science, reflecting its robust impact on the global scientific community. The journal aims to provide researchers, professionals, and students with high-quality articles that contribute significantly to the advancement of drug development and medicinal applications. Although it does not currently offer Open Access options, its rigorous peer-review process ensures that only the highest caliber research is published, making it a valuable resource for those seeking to stay at the forefront of pharmaceutical innovation.

Pharmaceutical Medicine is a leading journal published by SPRINGER INT PUBL AG, dedicated to the field of pharmacology and pharmaceutical sciences. With ISSN 1178-2595 and E-ISSN 1179-1993, this journal serves as an essential platform for researchers and professionals to share groundbreaking findings and advancements in medication efficacy, safety, and innovative therapeutic strategies. Recognized for its contribution to the field, Pharmaceutical Medicine holds an impressive Q2 ranking in both Pharmacology and Medical Pharmacology categories, further underscored by its competitive Scopus rankings—positioned at 100/272 (63rd percentile) in Medical Pharmacology and 156/313 (50th percentile) in Pharmacology, Toxicology, and Pharmaceutics. Although it primarily operates on a traditional subscription basis, its robust academic reputation continues to attract a diverse readership worldwide. Addressed in the United Kingdom with facilities in Switzerland, the journal publishes authoritative articles from its inception in 2000 through to 2024, making it a pivotal resource for those seeking to enhance their understanding and application of pharmacological principles in clinical practice and research.